| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA522: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
|
Medicine details |
|
| Medicine name | cytarabine/daunorubicin (Vyxeos®) |
| Formulation | 5 mg/ml and 2.2 mg/ml powder for concentrate for solution for infusion |
| Reference number | 1707 |
| Indication | Treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes |
| Company | Jazz Pharmaceuticals plc |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 31/07/2018 |
| NICE guidance | TA522: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |